*Giampietro Bertasi Department Of Orthopaedics, Italy
*Corresponding Author: Giampietro Bertasi
Department Of Orthopaedics, Italy Email:firstname.lastname@example.org
Published on: 2019-04-13
Nonunion treatment has a high rate of success, although recalcitrant nonunion may determine the need for amputation. Therefore, new treatment options are continuously investigated in order to further reduce the risk of nonunion recurrence.
Bone nonunion; Demineralized bone matrix
Fractures that no longer heal or show no bone union due to the cessation of reparative processes are classified as non-union fractures .This classification is typically diagnosed roughly 6 to 9 months following fracture [1, 3]. The diagnosis of non-unions includes pain at the fracture site, radiological signs during treatment, and impediments to motion . There are several treatments for non-union fractures. One of which is the use of cancellous bone allografts [3, 4]. These allografts allow for improved osteogenesis and also eliminate the donor site morbidity associated with autografts [3, 4, and 5]. Autologous bone graft is considered as the gold standard for all indications for bone grafting procedures but the limited availability and complications in donor site resulted in seeking other options like allografts and bone graft substitutes. Demineralized bone matrix (DBM) is an allograft product with no quantity limitation. It is an osteoconductive material with osteoinductive capabilities, which vary among different products, depending on donor characteristics and differences in processing of the bone .